Wednesday, May 22, 2024
Update At 14:00    USD/EUR 0,92  ↑+0.0002        USD/JPY 156,35  ↑+0.23        USD/KRW 1.362,23  ↓-1.05        EUR/JPY 169,69  ↑+0.256        Crude Oil 82,25  ↓-0.63        Asia Dow 3.985,41  ↓-34.92        TSE 1.794,50  ↓-6        Japan: Nikkei 225 38.654,05  ↓-292.88        S. Korea: KOSPI 2.728,33  ↑+4.15        China: Shanghai Composite 3.158,48  ↑+0.5137        Hong Kong: Hang Seng 19.254,80  ↑+34.18        Singapore: Straits Times 3,37  ↓-0.014        DJIA 22,28  ↑+0.052        Nasdaq Composite 16.832,63  ↑+37.75        S&P 500 5.321,41  ↑+13.28        Russell 2000 2.098,36  ↓-4.1443        Stoxx Euro 50 5.046,99  ↓-27.35        Stoxx Europe 600 522,95  ↓-0.94        Germany: DAX 18.726,76  ↓-42.2        UK: FTSE 100 8.416,45  ↓-7.75        Spain: IBEX 35 11.334,90  ↓-4.6        France: CAC 40 8.141,46  ↓-54.5        

Radiant reinvention: Saishunkan Pharmaceuticals’ pursuit of cosmetics excellence

Article - April 25, 2024

Saishunkan Pharmaceuticals leads with high-quality, medically-driven products like Domohorn Wrinkle, emphasizing innovation and excellence for global expansion.

Founded almost a century ago, Saishunkan Pharmaceutical has built its strategic success on quality, innovation, and global expansion.

"Japanese firms were slow to enter foreign markets," company president Masaaki Nishikawa explains. "However, we've embraced our unique value proposition and expanded overseas while maintaining our commitment to quality."

Despite Japan's demographic shift, Saishunkan has continued to focus on supporting customers through the various life stages.

"We are a company that provides products and services for the skin, body and mind, both domestically and overseas," Mr. Nishikawa says. "By collaborating with companies familiar with local markets, we can move more quickly and effectively."

Innovation is highlighted by the success of the Domohorn Wrinkle brand, which caters for any age or gender.

"We continually evolve this range to address customer needs, integrating traditional Chinese medicine concepts with the latest scientific research," the president states.

And there are ambitious goals for the future from Mr. Nishikawa, with Saishunkan aiming to become a JPY 10 billion company in terms of overseas business, one that clients believe is indispensable, and that has a vibrant work environment for employees.